Next Article in Journal
Construction of a Diagnostic m7G Regulator-Mediated Scoring Model for Identifying the Characteristics and Immune Landscapes of Osteoarthritis
Next Article in Special Issue
Review of Non-Eosinophilic Esophagitis-Eosinophilic Gastrointestinal Disease (Non-EoE-EGID) and a Case Series of Twenty-Eight Affected Patients
Previous Article in Journal
Structure of Photosystem I Supercomplex Isolated from a Chlamydomonas reinhardtii Cytochrome b6f Temperature-Sensitive Mutant
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 3
10.3390/biom13030538
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

by
Yuuki Sandhu
1,
Norihiro Harada
1,2,3,*,
Hitoshi Sasano
1,
Sonoko Harada
1,3,
Shoko Ueda
1,
Tomohito Takeshige
1,
Yuki Tanabe
1,
Ayako Ishimori
1,
Kei Matsuno
1,
Sumiko Abe
1,
Tetsutaro Nagaoka
1,
Jun Ito
1,
Asako Chiba
4,
Hisaya Akiba
4,
Ryo Atsuta
1,
Kenji Izuhara
5,
Sachiko Miyake
4 and
Kazuhisa Takahashi
1,2
1
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan
2
Research Institute for Diseases of Old Ages, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan
3
Atopy (Allergy) Research Center, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan
4
Department of Immunology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
5
Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga 849-8501, Japan
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(3), 538; https://doi.org/10.3390/biom13030538
Submission received: 25 January 2023 / Revised: 28 February 2023 / Accepted: 14 March 2023 / Published: 15 March 2023
(This article belongs to the Special Issue Eosinophils in Allergy and Related Diseases—Selected Papers from “The Workshop on Eosinophils in Allergy and Related Diseases 2022 and 2023”)
Browse Figures
Versions Notes

Abstract

Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine. Herein, we elucidated the dynamics of various parameters before and after treatment as well as patient characteristics predictive of clinical effectiveness after 1 year of benralizumab treatment in severe asthma in a real-world setting. Thirty-six patients with severe asthma were treated with benralizumab for 1 year. Lymphocyte subsets in peripheral blood samples were analyzed using flow cytometry. Treatment effectiveness was determined based on the ACT score, forced expiratory volume in 1 s (FEV1), and the number of exacerbations. Benralizumab provided symptomatic improvement in severe asthma. Benralizumab significantly decreased peripheral blood eosinophil and basophil counts and the frequencies of regulatory T cells (Tregs), and increased the frequencies of Th2 cells. To our knowledge, this is the first study to show benralizumab treatment increasing circulating Th2 cells and decreasing circulating Tregs. Finally, the ROC curve to discriminate patients who achieved clinical effectiveness of benralizumab treatment revealed that the frequency of circulating Th17 cells and FeNO levels might be used as parameters for predicting the real-world response of benralizumab treatment in patients with severe asthma.
Keywords: asthma; benralizumab; FeNO; Th17 cells; real-world setting asthma; benralizumab; FeNO; Th17 cells; real-world setting

Share and Cite

MDPI and ACS Style

Sandhu, Y.; Harada, N.; Sasano, H.; Harada, S.; Ueda, S.; Takeshige, T.; Tanabe, Y.; Ishimori, A.; Matsuno, K.; Abe, S.; et al. Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules 2023, 13, 538. https://doi.org/10.3390/biom13030538

AMA Style

Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T, Tanabe Y, Ishimori A, Matsuno K, Abe S, et al. Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules. 2023; 13(3):538. https://doi.org/10.3390/biom13030538

Chicago/Turabian Style

Sandhu, Yuuki, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, and et al. 2023. "Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma" Biomolecules 13, no. 3: 538. https://doi.org/10.3390/biom13030538

APA Style

Sandhu, Y., Harada, N., Sasano, H., Harada, S., Ueda, S., Takeshige, T., Tanabe, Y., Ishimori, A., Matsuno, K., Abe, S., Nagaoka, T., Ito, J., Chiba, A., Akiba, H., Atsuta, R., Izuhara, K., Miyake, S., & Takahashi, K. (2023). Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules, 13(3), 538. https://doi.org/10.3390/biom13030538

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop